ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Quotient Therapeutics, a start-up launched by venture firm Flagship Pioneering late last year, is collaborating with Pfizer. The companies will use Quotient’s technology to analyze mutations in DNA sequences or cellular genomes. The somatic mutations the firms identify will guide development of new drug candidates for cardiovascular and kidney diseases. The partnership is part of an existing agreement between Pfizer and Flagship’s Pioneering Medicines initiative. That effort has sparked collaborations between Flagship-backed firms and Novo Nordisk, the Cystic Fibrosis Foundation, and, recently, GSK.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X